Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name GL-ONC1
Trade Name
Synonyms GLV-1h68|Olvimulogene nanivacirepvec|Olvi-Vec
Drug Descriptions

Olvimulogene nanivacirepvec (GL-ONC1) is a genetically engineered light-emitting oncolytic vaccinia virus, which results in viral infection within the cells, thereby possibly inducing cell death and interruption of the cell cycle (PMID: 28679776, PMID: 31567308).

CAS Registry Number NA
NCIT ID C79833


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Bevacizumab + Carboplatin + GL-ONC1 Bevacizumab Carboplatin GL-ONC1 0 1
Bevacizumab + Cisplatin + GL-ONC1 Bevacizumab Cisplatin GL-ONC1 0 1
Cisplatin + GL-ONC1 + Radiotherapy Cisplatin GL-ONC1 Radiotherapy 0 0

Additional content available in CKB BOOST